戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 alopram) and tricyclic antidepressants (e.g. clomipramine).
2  but not acute, treatment with fluoxetine or clomipramine.
3 the allosteric potency of (S)-citalopram and clomipramine.
4 f inadequate response or intolerance to oral clomipramine.
5 disorder (OCD) who are nonresponsive to oral clomipramine.
6  imipramine, desipramine, amitriptyline, and clomipramine.
7 s and 172 patients), behavioural therapy and clomipramine (-12.97 [-19.18 to -6.74]; one trial and 31
8                                        Pulse clomipramine (200 mg i.v.) is associated with dramatic r
9 18) were randomly assigned to receive either clomipramine (200 mg i.v., N = 8) or saline (N = 8).
10 e present study a single intravenous dose of clomipramine (200 mg) was compared with saline placebo i
11 10 to -1.63]; nine trials and 231 patients), clomipramine (-4.72 [-6.85 to -2.60]; 13 trials and 831
12 osure and ritual prevention, 42% and 48% for clomipramine, 70% and 79% for exposure and ritual preven
13 eek, double-blind, crossover-design study of clomipramine, a potent serotonin reuptake inhibitor, and
14 by eight weekly maintenance sessions, and/or clomipramine administered for 12 weeks, with a maximum d
15               Cocrystal structures show that clomipramine, along with two other TCAs, binds in an ext
16 o test the relative and combined efficacy of clomipramine and exposure and ritual prevention in the t
17  of 21 patients initially randomized to i.v. clomipramine and treated subsequently with oral clomipra
18 ure and ritual prevention may be superior to clomipramine and, by implication, to monotherapy with th
19 xetine, citalopram, reboxetine, venlafaxine, clomipramine) and atypical antidepressants (agomelatine,
20 ination (exposure and ritual prevention plus clomipramine), and pill placebo was conducted at one cen
21  79% for exposure and ritual prevention plus clomipramine, and 8% and 10% for placebo.
22  that of exposure and ritual prevention plus clomipramine, and both were superior to clomipramine onl
23 exposure to the 5-HTT inhibitors fluoxetine, clomipramine, and citalopram from postnatal day 4 (P4) t
24 e-blind oral or intravenous pulse loading of clomipramine, and patients were then given 150 mg/day of
25  imipramine, desipramine, amitriptyline, and clomipramine are predicted using density functional theo
26 ose, six of seven patients given intravenous clomipramine but only one of eight given oral medication
27 of mice for 3 weeks with one of these drugs, clomipramine, causes nearly 50% reduction in the levels
28  determination of amitriptyline, citalopram, clomipramine, chlorpromazine, doxepin, haloperidol, nort
29                 Previous research found that clomipramine (CLI) treatment of neonatal rats produced,
30 ression, produced by neonatal treatment with clomipramine (CLI).
31 nts reboxetine (REB), paroxetine (PAROX) and clomipramine (CLOM) on extracellular DA in rats using mi
32   Patients taking antidepressants, including Clomipramine (CLP), have an increased risk of osteoporot
33                Chronic postnatal exposure to clomipramine (CMI), a monoamine uptake inhibitor, result
34 ys, we showed that inhibiting autophagy with clomipramine (CMI), chloroquine or metformin increased a
35 ix patients who had responded to intravenous clomipramine continued their improvement, but those who
36 evious open-label trial of pulse intravenous clomipramine demonstrated rapid relief of depressive sym
37 ncluded trials of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, flu
38   Amitriptyline, nortriptyline, desipramine, clomipramine, dothiepin, and sertraline were not found i
39 : amitriptyline, nortriptyline, desipramine, clomipramine, doxepin, dothiepin, fluoxetine, sertraline
40                                              Clomipramine, exposure and ritual prevention, and their
41 fluoxetine, fluvoxamine, and sertraline) and clomipramine, four study designs, four dependent outcome
42 ncontrolled reports suggest that intravenous clomipramine hydrochloride may be effective for patients
43 to receive 14 infusions of either placebo or clomipramine hydrochloride, starting at 25 mg/d and incr
44  of intravenous versus oral pulse loading of clomipramine in patients with obsessive-compulsive disor
45                  A tricyclic antidepressant, clomipramine, instead mirrored the behavior of the selec
46                                              Clomipramine is more effective than desipramine in the t
47                                  Intravenous clomipramine is more effective than i.v. placebo for pat
48 it mammalian ASM activities, desipramine and clomipramine, markedly extend the lifespan of wild-type
49                 Intravenous pulse loading of clomipramine may be a valuable new treatment for obsessi
50 show that the tricyclic antidepressant (TCA) clomipramine noncompetitively inhibits substrate uptake.
51 plus clomipramine, and both were superior to clomipramine only.
52 ts were treated with the TCAs nortriptyline, clomipramine, or imipramine, with clinical follow-up of
53                                 Furthermore, clomipramine, paroxetine, and desipramine were able to i
54  3 representatively selected antidepressants clomipramine, paroxetine, and desipramine.
55               Off-rate assays establish that clomipramine reduces the rate at which leucine dissociat
56                Fifty-four patients with oral clomipramine-refractory OCD were randomized to receive 1
57 quently with several days of open-label i.v. clomipramine responded (df = 1, P<.002).
58 cy for multiple inhibitors such as (RS)-CIT, clomipramine, RTI-55, fluoxetine, cocaine, nisoxetine, m
59                      These data suggest that clomipramine's possibly superior efficacy in the treatme
60                        After 8 weeks of oral clomipramine, the results partially supported the second
61 al comparing exposure and ritual prevention, clomipramine, their combination (exposure and ritual pre
62                                 Seven of the clomipramine-treated patients and three of the saline-tr
63           The adolescents who received pulse clomipramine treatment demonstrated significant decrease
64                                  Intravenous clomipramine treatment was safe with no serious adverse
65 l continue to improve during 8 weeks of oral clomipramine treatment.
66 nts randomized to receive intravenous (i.v.) clomipramine vs 0 of 25 patients given i.v. placebo were
67                                              Clomipramine was also superior to desipramine in improvi
68                                    Likewise, clomipramine was equally effective regardless of whether
69                                              Clomipramine was not better than were SSRIs (-1.23 [-3.4
70  with other variables controlled showed that clomipramine was significantly superior to each of the S
71                                              Clomipramine was superior to desipramine in the acute tr
72 mipramine and treated subsequently with oral clomipramine were responders, whereas 0 of 18 patients i
73  patients were then given 150 mg/day of oral clomipramine with increases of 25 mg every 4 days to 250
74 uld adolescents who received saline and that clomipramine would be superior to saline in terms of ant
75 that adolescents who were treated with pulse clomipramine would exhibit lower scores on the Hamilton